ReviewIndian journal of ophthalmology2026
Perioperative anti-vascular endothelial growth factor treatment in diabetic vitrectomy: A narrative review.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rising prevalence of diabetes mellitus globally, vision-threatening diabetic retinopathy (DR) is also rapidly increasing. Due to the advent of newer instrumentation, the indications of pars plana vitrectomy (PPV) in such advanced DR patients have also expanded. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are also increasingly being used in patients with DR, often as an adjunct to PPV. This narrative review was conducted to summarize and critically analyze the role of perioperative anti-VEGF therapy in diabetic vitrectomy. Various indications of diabetic vitrectomy where perioperative anti-VEGF is used have been elucidated. Controversies regarding the optimal timing of preoperative anti-VEGF therapy prior to vitrectomy have been addressed in detail. This review also elaborates the various intraoperative and postoperative benefits of anti-VEGFs with regard to the duration of vitrectomy, intraoperative bleeding, iatrogenic breaks, need for endodiathermy and silicon oil endotamponade, surgical difficulty score, postoperative visual gain, intraocular pressures, postoperative vitreous cavity hemorrhage, and need for second surgery. The current narrative also mentions the potential ocular adverse effects of anti-VEGF, such as progression of tractional retinal detachment, apart from addressing other ocular side effects and a few other uncommon yet serious systemic adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.